|
Additional information in following fields- b2: outcomes attributed to adverse event, b4: date of this report, b5: additional narrative, d8-9: device available for evaluation and returned to manufacturer date, g3: date received by manufacturer, h3: device evaluated by manufacturer, h6: impact code and evaluation codes
corrected data in following fields ¿ d4: unique identifier (udi) number
this follow-up report is being submitted to relay additional and corrected information.The spinalpak assembly was received for evaluation but due to the nature of the complaint and the information provided within the complaint file, only the spinalpak stimulator was evaluated.A visual inspection of the customer returned product was performed.The part received looks to be in good condition from the visual/cosmetic point of view.The compliance data for the spinalpak stimulator was downloaded on may 28, 2026.The compliance data indicates the unit treated for 8 days 6 hours and 36 minutes.Review of the dhr indicates that unit was manufactured on october 21, 2025.There were no non-conformances or deviations reported on the dhr.The spinalpak unit ran for on battery power only for more than 24 hours with no problem.The measured output period was 16.4 usec (specification - output period from 15.2usec ¿ 18.5usec) ¿¿pass¿.The measured output amplitude was 5.6 vpp (specification - output amplitude from 5.4vpp ¿ 6.4vpp) ¿¿pass".Review of the information provided by the customer and the findings from the investigation indicated that no physical and/or device functional condition could be found that could be considered a causal factor for the reported complaint of "pain".No failure and/or fault condition could be found and confirmed.Therefore, no further actions are required at this time.Review of complaint history identified (34) total complaints from (january 21, 2025) to (january 21, 2026) for pn (1067716, 1067717) and events related to (pain).The search could not be specified further because the main complaint was pain.The device is used for treatment.Ebi will continue to monitor trends.
|